Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Oncology Reports|June 16, 2000
Treatment of large cell lymphoma with the Fi2 regimen (doxorubicin, vincristine, cyclophosphamide, bleomycin and prednisone): 25-year experienceG Bellesi, L Rigacci, G Longo, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 10, 1998
Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicityP Pouillart, O Douillet, B Scappini, et al.
Leukemia & Lymphoma|February 1, 1996
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderlyG Bellesi, L Rigacci, R Alterini, et al.
Leukemia Research|August 4, 2009
Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and RituximabC Rabascio, D Laszlo, G Andreola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 3, 2010
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)A Conconi, G Martinelli, A Lopez-Guillermo, et al.
British Journal of Haematology|December 19, 1998
Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNAA M Vannucchi, A Bosi, S Glinz, et al.
International Journal of Radiation Oncology, Biology, Physics|April 5, 2001
The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University HospitalE Cellai, S M Magrini, G Masala, et al.
Blood|January 29, 2000
Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano LinfomiM Federico, U Vitolo, P L Zinzani, et al.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Pageof 3